Pharmala Biotech Holdings (XCNQ:MDMA) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XCNQ:MDMA Pharmala Biotech Holdings Inc XCNQ:MDMA
38 GF Score
Price C$0.25
GF Value C$0.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pharmala Biotech Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XCNQ:MDMA vs VRTX, REGN, RVMD: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Pharmala Biotech Holdings's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Margin of Safety % (DCF Earnings Based) falls into.


XCNQ:MDMA
38GF Score
Pharmala Biotech Holdings Inc XCNQ:MDMA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmala Biotech Holdings (XCNQ:MDMA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of C$0.25 is trading 0% below its estimated GF Value™ of C$0.25. GuruFocus considers Pharmala Biotech Holdings to be Fairly Valued.

Key valuation signals for XCNQ:MDMA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: C$0.25 vs. price of C$0.25 (0% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the XCNQ:MDMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDXXF:USA
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
38GF Score

Get the complete analysis for XCNQ:MDMA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.25
Price
C$0.25
GF Value